IPC The Hospitalist
The 10-second takeaway
For the quarter ended March 31 (Q1), IPC The Hospitalist beat slightly on revenues and beat slightly on earnings per share.
Compared to the prior-year quarter, revenue grew and GAAP earnings per share grew.
Margins dropped across the board.
IPC The Hospitalist logged revenue of $129.8 million. The 11 analysts polled by S&P Capital IQ predicted revenue of $128.3 million on the same basis. GAAP reported sales were 14% higher than the prior-year quarter's $113.4 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.50. The 12 earnings estimates compiled by S&P Capital IQ predicted $0.49 per share. GAAP EPS of $0.50 for Q1 were 8.7% higher than the prior-year quarter's $0.46 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 26.7%, 90 basis points worse than the prior-year quarter. Operating margin was 10.6%, 70 basis points worse than the prior-year quarter. Net margin was 6.6%, 20 basis points worse than the prior-year quarter.
Next quarter's average estimate for revenue is $128.0 million. On the bottom line, the average EPS estimate is $0.46.
Next year's average estimate for revenue is $523.3 million. The average EPS estimate is $2.00.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 70 members out of 75 rating the stock outperform, and five members rating it underperform. Among 16 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 16 give IPC The Hospitalist a green thumbs-up, and none give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on IPC The Hospitalist is outperform, with an average price target of $39.50.
The healthcare investing landscape is littered with also-rans and a few major winners. Is IPC The Hospitalist prepared for the future? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company David Gardner believes will deliver amazing returns during the next few years. Click here for instant access to this free report.
- Add IPC The Hospitalist to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.